Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 563-570

  Pithavala, Y K ^a   Tortorici, M ^a   Toh, M ^a,c   Garrett, M ^a   Hee, B ^a   Kuruganti, U ^b   Ni, G ^b   Klamerus, K J ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

^c Pfizer Ophthalmology ^*  (Hong Kong)

Author keywords

Adverse drug events; Anticancer agents; Ethnic groups; Healthy volunteers; Pharmacokinetics; Plasma drug concentrations

Indexed keywords

AXITINIB; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A1; RIFAMPICIN; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ENZYME INHIBITOR; GLUCURONOSYLTRANSFERASE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; ETHNICITY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ASIAN; BLOOD; CROSSOVER PROCEDURE; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; IMIDAZOLES; INDAZOLES; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RIFAMPIN; YOUNG ADULT;

EID: 75549086120     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1065-y     Document Type: Article

References (24)

1. DD Hu-Lowe HY Zou ML Grazzini ME Hallin GR Wickman K Amundson JH Chen DA Rewolinski S Yamazaki EY Wu MA McTigue BW Murray RS Kania P O'Connor DR Shalinsky SL Bender 2008 Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272 7283 10.1158/1078-0432.CCR-08-0652 10.1158/1078-0432.CCR-08-0652 1:CAS:528:DC%2BD1cXhtlylur7I 19010843
2. O Rixe RM Bukowski MD Michaelson G Wilding GR Hudes O Bolte RJ Motzer P Bycott KF Liau J Freddo PC Trask S Kim BI Rini 2007 Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 975 984 10.1016/S1470-2045(07)70285-1 10.1016/S1470-2045(07) 70285-1 17959415 (Pubitemid 47629888)
3. E Cohen LS Rosen EE Vokes MS Kies A Forastiere F Worden MA Kane E Sherman S Kim P Bycott M Tortorici DR Shalinsky KF Liau RB Cohen 2008 Axitinib is an active treatment for all histological subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 4708 4713 10.1200/JCO.2007.15.9566 10.1200/JCO.2007.15.9566 1:CAS:528:DC%2BD1cXhtlSqsLfE 18541897
4. JH Schiller T Larson SI Ou A Limentani AB Sandler EE Vokes S Kim KF Liau PW Bycott 2007 Efficacy and safety of axitinib (AG-013736) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial J Clin Oncol 25 386s
5. JP Spano C Chodkiewicz J Maurel R Wong H Wasan C Barone R Letourneau E Bajetta Y Pithavala P Bycott P Trask K Liau AD Ricart S Kim O Rixe 2008 Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 2101 2108 10.1016/S0140-6736(08)60661-3 10.1016/S0140-6736(08)60661-3 1:CAS:528:DC%2BD1cXnsFGjurs%3D 18514303
6. HS Rugo A Stopeck AA Joy S Chan S Verma A Lluch KF Liau S Kim P Boycott D Soulieres 2007 A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) J Clin Oncol 25 32s
7. HS Rugo RS Herbst G Liu JW Park MS Kies HM Steinfeldt YK Pithavala SD Reich JL Freddo G Wilding 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483 10.1200/JCO.2005.04.192 10.1200/JCO.2005.04. 192 1:CAS:528:DC%2BD2MXhtVersr7F 16027439 (Pubitemid 46300140)
8. Pithavala Y, Klamerus KJ, Mount J, Garrett M, Hee B, Selaru P, Sarapa N (2008) Effect of ketoconazole on the pharmacokinetics of axitinib (AG-013736) in healthy volunteers. American Association for Cancer Research (AACR) Annual meeting, April 12-16, 2008, San Diego Convention Center, San Diego, Abstract 232
9. M Niemi JT Backman MF Fromm PJ Neuvonen KT Kivistö 2003 Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 42 819 850 10.2165/00003088-200342090-00003 1:CAS:528: DC%2BD3sXntl2htr8%3D 12882588 (Pubitemid 36995083)
10. JM Rae MD Johnson ME Lippman DA Flockhart 2001 Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays J Pharmacol Exp Ther 299 849 857 1:CAS:528:DC%2BD3MXovVCktr4%3D 11714868
11. M Nishimura A Koeda T Shimizu M Nakayama T Satoh S Narimatsu S Naito 2008 Comparison of inducibility of sulfotransferase and UDP-glucuronosyltransferase mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes Drug Metab Pharmacokinet 23 45 53 10.2133/dmpk.23.45 10.2133/dmpk.23.45 1:CAS:528:DC%2BD1cXkvFegt74%3D 18305373
12. G Monaghan M Ryan R Seddon R Hume B Burchell 1996 Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 578 581 10.1016/S0140-6736(96)91273-8 10.1016/S0140-6736(96)91273-8 1:CAS:528:DyaK28XitVGrtrc%3D 8596320 (Pubitemid 26070740)
13. E Beutler T Gelbart A Demina 1998 Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95 8170 8174 10.1073/pnas.95.14.8170 1:CAS:528:DyaK1cXks1Skur4%3D 9653159 (Pubitemid 28326085)
14. Y Ando M Chida K Nakayama H Saka T Kamataki 1998 The UGT1A128 allele is relatively rare in a Japanese population Pharmacogenetics 8 357 360 10.1097/00008571-199808000-00010 1:CAS:528:DyaK1cXlvVWqtbc%3D 9731723 (Pubitemid 28372330)
15. JW Lampe J Bigler NK Horner JD Potter 1999 UDP-glucuronosyltransferase (UGT1A128 and UGT1A62) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations Pharmacogenetics 9 341 349 10.1097/00008571- 199906000-00009 1:CAS:528:DyaK1MXlsFGls7w%3D 10471066
16. L Iyer D Hall S Das MA Mortell J Ramirez S Kim RA Di MJ Ratain 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 576 582 10.1016/S0009-9236(99) 70078-0 1:CAS:528:DyaK1MXjslSrt74%3D 10340924 (Pubitemid 29237332)
17. D Hall G Ybazeta G stro-Bisol ML Petzl-Erler RA Di 1999 Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates Pharmacogenetics 9 591 599 10.1097/00008571-199910000- 00006 1:CAS:528:DyaK1MXotFOitbc%3D 10591539
18. Y Ando H Saka M Ando T Sawa K Muro H Ueoka A Yokoyama S Saitoh K Shimokata Y Hasegawa 2000 Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921 6926 1:CAS:528:DC%2BD3MXjsVOjsA%3D%3D 11156391
19. J Sugatani K Yamakawa K Yoshinari T Machida H Takagi M Mori S Kakizaki T Sueyoshi M Negishi M Miwa 2002 Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia Biochem Biophys Res Commun 292 492 497 10.1006/bbrc.2002.6683 1:CAS:528:DC%2BD38XitFeitLs%3D 11906189 (Pubitemid 34694291)
20. KY Fertrin MS Gonçalves ST Saad FF Costa 2002 Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil Am J Med Genet 108 117 119 10.1002/ajmg.10209 10.1002/ajmg.10209 1:STN:280:DC%2BD387it1SrsA%3D%3D 11857560 (Pubitemid 34174314)
21. JL Fang FA Beland DR Doerge D Wiener C Guillemette MM Marques P Lazarus 2002 Characterization of benzo(a)pyrene-trans-7, 8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes Cancer Res 62 1978 1986 1:CAS:528:DC%2BD38XivVyltbs%3D 11929814
22. C Kitagawa M Ando Y Ando Y Sekido K Wakai K Imaizumi K Shimokata Y Hasegawa 2005 Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity Pharmacogenet Genomics 15 35 41 10.1097/01213011-200501000-00006 1:CAS:528:DC%2BD2MXitl2ku78%3D 15864124
23. EE Ohnhaus AM Breckenridge BK Park 1989 Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man Eur J Clin Pharmacol 36 39 46 10.1007/BF00561021 1:CAS:528:DyaL1MXht1yju7w%3D 2917586 (Pubitemid 19052008)
24. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M (2009) Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir. Antimicrob Agents Chemother [Epub ahead of print]. doi: 10.1128/AAC.01468-08